0001062993-24-012734.txt : 20240617
0001062993-24-012734.hdr.sgml : 20240617
20240617203839
ACCESSION NUMBER: 0001062993-24-012734
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240617
FILED AS OF DATE: 20240617
DATE AS OF CHANGE: 20240617
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kieffer Tara Lynn
CENTRAL INDEX KEY: 0001834835
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35839
FILM NUMBER: 241049921
MAIL ADDRESS:
STREET 1: C/O ENANTA PHARMACEUTICALS, INC.
STREET 2: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001177648
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617 607 0800
MAIL ADDRESS:
STREET 1: 500 ARSENAL STREET
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-06-17
0001177648
ENANTA PHARMACEUTICALS INC
ENTA
0001834835
Kieffer Tara Lynn
C/O ENANTA PHARMACEUTICALS, INC.
500 ARSENAL STREET
WATERTOWN
MA
02472
0
1
0
0
Chief Product Strategy Officer
1
Common Stock
2024-06-17
4
S
0
7266
12.33
D
32341
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2024.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.54, inclusive.
The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 above.
/s/ Paul J. Mellett as attorney-in-fact
2024-06-17